Compare Quest Diagnostics Inc (DGX) vs abrdn Physical Palladium Shares ETF (PALL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs abrdn Physical Palladium Shares ETF — how do they compare? Quest Diagnostics Inc trades at $204.68 (market cap $22.80B), while abrdn Physical Palladium Shares ETF trades at $23.73. The key difference: Quest Diagnostics Inc pays a 1.67% dividend while abrdn Physical Palladium Shares ETF pays none, and Quest Diagnostics Inc is trading nearer its 52-week high, abrdn Physical Palladium Shares ETF nearer its low. Which is the better fit depends on your goals.
| DGX | PALL | |
|---|---|---|
Market Cap | $22.80B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $216.02 | $37.18 |
52-Week Low | $166.42 | $19.96 |
Enterprise Value | $28.82B | — |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
PALL (abrdn Physical Palladium Shares ETF) trades at $22.73, down 1.47% with bearish technical signals from moving averages. The ETF faces headwinds from palladium's 47% price decline from January 2026 highs, though recent news highlights potential buying opportunities as the metal approaches technical support levels. A 1:5 stock split occurred on May 18, 2026, which adjusted share count without changing the fund's total value.
The outlook remains cautious due to weak palladium pricing and industrial demand concerns, though some analysts see value at current levels. Key risks include commodity price volatility and Federal Reserve policy impacts. Investment appeal hinges on palladium's supply-demand dynamics improving from current depressed conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About abrdn Physical Palladium Shares ETF
PALL is a physically-backed ETF that tracks the spot price of palladium. It holds physical bullion in secure vaults, offering a liquid way to invest in this precious metal primarily used in automotive catalytic converters and electronics.
Read more on PALL →
